+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020

  • ID: 4986883
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 86 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Bionevia Pharmaceuticals
  • Celularity Inc
  • GNT Pharma Co Ltd
  • Medifron DBT Co Ltd
  • Reata Pharmaceuticals Inc
  • MORE
Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 3, 1, 9 and 1 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Achelios Therapeutics Inc
  • Bionevia Pharmaceuticals
  • Celularity Inc
  • GNT Pharma Co Ltd
  • Medifron DBT Co Ltd
  • Reata Pharmaceuticals Inc
  • MORE
  • Introduction
  • Report Coverage
  • Diabetic Peripheral Neuropathy - Overview
  • Diabetic Peripheral Neuropathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Diabetic Peripheral Neuropathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Bionevia Pharmaceuticals
  • Calchan Ltd
  • Celularity Inc
  • Cleveland Diabetes Care Inc
  • Commence Bio Inc
  • CSPC Pharmaceutical Group Ltd
  • Exodos Life Sciences Limited Partnership
  • GNT Pharma Co Ltd
  • Grunenthal GmbH
  • Immune Pharmaceuticals Inc
  • Ion Channel Pharmacology LLC
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • Medifron DBT Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Praetego Inc
  • Reata Pharmaceuticals Inc
  • Seneca Biopharma Inc
  • Sonnet BioTherapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Winsantor Inc
  • YD Life Science Co
  • Zhejiang Pharmaceutical Co Ltd
  • Diabetic Peripheral Neuropathy - Drug Profiles
  • (amitriptyline + ketamine hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Diabetic Peripheral Neuropathy - Dormant Projects
  • Diabetic Peripheral Neuropathy - Discontinued Products
  • Diabetic Peripheral Neuropathy - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Applied Therapeutics Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Bionevia Pharmaceuticals, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Calchan Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Celularity Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Cleveland Diabetes Care Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by GNT Pharma Co Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Ion Channel Pharmacology LLC, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Praetego Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Seneca Biopharma Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Winsantor Inc, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by YD Life Science Co, H1 2020
  • Diabetic Peripheral Neuropathy - Pipeline by Zhejiang Pharmaceutical Co Ltd, H1 2020
  • Diabetic Peripheral Neuropathy - Dormant Projects, H1 2020
  • Diabetic Peripheral Neuropathy - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Bionevia Pharmaceuticals
  • Calchan Ltd
  • Celularity Inc
  • Cleveland Diabetes Care Inc
  • Commence Bio Inc
  • CSPC Pharmaceutical Group Ltd
  • Exodos Life Sciences Limited Partnership
  • GNT Pharma Co Ltd
  • Grunenthal GmbH
  • Immune Pharmaceuticals Inc
  • Ion Channel Pharmacology LLC
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • Medifron DBT Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Praetego Inc
  • Reata Pharmaceuticals Inc
  • Seneca Biopharma Inc
  • Sonnet BioTherapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Winsantor Inc
  • YD Life Science Co
  • Zhejiang Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll